CoChat

Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening

Open access
Rabe, Christina, Bittner, Tobias, Jethwa, Alexander, Suridjan, Ivonne, Manuilova, Ekaterina, Friesenhahn, Michel, Stomrud, Erik, Zetterberg, Henrik, Blennow, Kaj, Hansson, Oskar, for the Alzheimer's Disease Neuroimaging Initiative and the Swedish BioFINDER study · 2023 · Alzheimer's & Dementia
Cited by 89

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Introduction: Further evidence is needed to support the use of plasma amyloid β (Aβ) biomarkers as Alzheimer's disease prescreening tools. This study evaluated the clinical performance and robustness of plasma Aβ 42/Aβ 40 for amyloid positivity prescreening. Methods: Data were collected from 333 BioFINDER and 121 Alzheimer's Disease Neuroimaging Initiative study participants. Risk and predictive values versus percentile of plasma Aβ 42/Aβ 40 evaluated the actionability of plasma Aβ 42/Aβ 40, and simulations modeled the impact of potential uncertainties and biases. Amyloid PET was the brain amyloidosis reference standard. Results: Elecsys plasma Aβ 42/Aβ 40 could potentially rule out amyloid pathology in populations with low‐to‐moderate amyloid positivity prevalence. However, simulations showed small measurement or pre‐analytical errors in Aβ 42 and/or Aβ 40 cause misclassifications, impacting sensitivity or specificity. The minor fold change between amyloid PET positive and negative cases explains the biomarkers low robustness. Discussion: Implementing plasma Aβ 42/Aβ 40 for routine clinical use may pose significant challenges, with misclassification risks. Highlights: Plasma Aβ 42/Aβ 40 ruled out amyloid PET positivity in a setting of low amyloid‐positive prevalence. Including (pre‐) analytical errors or measurement biases caused misclassifications. Plasma Aβ 42/Aβ 40 had a low inherent dynamic range, independent of analytical method. Other blood biomarkers may be easier to implement as robust prescreening tools.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.12801

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 89

Metadata

Authors
Rabe, C., Bittner, T., Jethwa, A., Suridjan, I., Manuilova, E., Friesenhahn, M., Stomrud, E., Zetterberg, H., Blennow, K., Hansson, O., & study, F. T. A. D. N. I. A. T. S. B.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2022-09-23
Volume
19
Issue
4
Pages
1393-1402
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W4297036157
Cited by
89
References
15
FWCI
10.04
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening. https://app.cochat.ai/papers/10.1002/alz.12801
The paper
Rabe, C., Bittner, T., Jethwa, A., Suridjan, I., Manuilova, E., Friesenhahn, M., Stomrud, E., Zetterberg, H., Blennow, K., Hansson, O., & study, F. T. A. D. N. I. A. T. S. B. (2023). Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12801

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.